



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE. SUITE 2400 AUSTIN. TEXAS 78701-3271 WWW.FULBRIGHT.COM

MARK B. WILSON PARTNER MBWILSON@FULBRIGHT.COM

DIRECT DIAL:

(512) 536-3035

TELEPHONE:

(512) 474-5201

FACSIMILE:

(512) 536-4598

April 14, 2003

CERTIFICATE OF MAILING 37 C.F R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Box Sequence, Commissioner for Patents, P Q Box 2327 Arlington, VA 22202, on the date

April 14, 2003

Date

BOX SEQUENCE

Commissioner for Patents P.O. Box 2327 Arlington, VA 22202

RE:

U.S. Patent Application No. 10/043,639 entitled "METHOD FOR PREPARING 1,3-PROPANEDIOL BY A RECOMBINANT MICRO-ORGANISM IN THE ABSENCE OF COENZYME B12 OR ONE OF ITS PRECURSORS" – Patricia Sarcabal et al. Our reference: CHEP:004US

Client reference: K616 PCT/US

Sir:

Please find enclosed:

- A Response to Notice to Comply with Requirements for Patent Applications Containing (1) Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed February 13,
- Statement as Required Under 37 C.F.R. § 1.825(a) and (b) and Statement as Required (2) Under 37 C.F.R. § 1.821(g);

MOLISTON • NEW YORK • MASHINSTON DC • ALISTIN • DALLAS • LOS ANSELES • MINNEAPOLIS • BAN ANTONIO • MONBIYUNS • LONGUN • MUNICIA

- (3) Computer Readable Form of Sequence Listing;
- Paper Copy of Sequence Listing; (4)

25285022.1

2nd Page Header Text April 14, 2003 Page 2

- (5) Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures; and
- (6) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/CHEP:004US.

Respectfully submitted,

Mark B. Wilson Reg. No. 37,259

MBW/mar Encl: as noted



Commissioner for Patents Washington, DC 20231 www.uspto.gov

10.043,639

Mark B. Wilson

01/09/2002

Patricia Sarcabal

CHIP HATS

CONFIRMATION NO. 6528 FORMALITIES LETTER

OC000000009512037

Fulbright & Jaworski L.L.P. Suite 2400 600 Congress Avenue Austin, TX 78701

Date Mailed: 02/13/2003

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

 The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f). 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

La Principal O Customer Service Center Imital Patent I Xanun aton Division [7/3/3/8-12/2







IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Patricia Sarcabal et al.

Serial No.: 10/043,639

Filed: January 9, 2002

For: METHOD FOR PREPARING 1,3-

PROPANEDIOL BY A RECOMBINANT MICRO-ORGANISM IN THE ABSENCE OF COENZYME B12 OR ONE OF ITS

PRECURSORS

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: CHEP:004US

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Box Sequence, Commissioner for Patents, P.O. Box 2327, Arlington, VA 22202, on the date the ow:

April 14, 2003

Date

Mark B. Wilson

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

BOX SEQUENCE

Commissioner for Patents P.O. Box 2327 Arlington, VA 22202

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, dated February 13, 2003, there are enclosed herewith:

(a) Statement as Required Under 37 C.F.R. § 1.825(a) and (b) and Statement as Required Under 37 C.F.R. § 1.821(g);

(b) Computer Readable Form of Sequence Listing;

(c) Paper Copy of Sequence Listing;

(d) A copy of Notice to Comply with Requirements for Patent Applications

Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures; and

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from

Fulbright & Jaworski Deposit Account No.: 50-1212/CHEP:004US.

Please date stamp and return the accompanying postcard to evidence receipt of these documents.

Respectfully submitted,

Mark B. Wilson Reg. No. 37,259

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date: April 14, 2003